Sabio lab

at the CNIC

Tag: liver (page 1 of 3)

Organ crosstalk in energy balance and metabolic disease (8-11 April 2018)

We are organizing an EMBO Workshop to provide the most important and up-to-date research in the field of metabolism. The workshop will focus on understanding the recent progress in adipocyte biology (cell fate and browning), liver metabolism including steatosis and the role of the central nervous system in the control of the energy homeostasis. Special emphasis will be done to highlight the importance of the organ crosstalk and how signalling pathways in one tissue could affect the metabolism in other tissue.

The goals of this EMBO Workshop are to provide important new insights into the primary pathogenesis of these disorders, and especially focus on those that might lead to new therapies.

¿Quién dirige la orquesta en la obesidad? (15 March 2018)

On Thursday 15 March 2018, at the XIV Congress of the Spanish Society for the Study of the Obesity (SEEDO) Guadalupe Sabio (Centro Nacional de Investigaciones Cardiovasculares Carlos III) and Amaia Rodríguez Murueta-Goyena (Clínica Universidad de Navarra) will debate about which is the main organ orchestrating the diseases caused by obesity.

SEEDO 2018

Pharmacological stimulation of p53 with low-dose doxorubicin ameliorates diet-induced nonalcoholic steatosis and steatohepatitis

Begoña Porteiro, Marcos F. Fondevila, Xabier Buque, Maria J. Gonzalez-Rellan, Uxia Fernandez, Alfonso Mora, Daniel Beiroa, Ana, Senra, Rosalia Gallego, Johan Fernø, Miguel López, Guadalupe Sabio, Carlos Dieguez, Patricia Aspichueta & Rubén Nogueiras.

Recent reports have implicated the p53 tumor suppressor in the regulation of lipid metabolism. We hypothesized that the pharmacological activation of p53 with low-dose doxorubicin, which is widely used to treat several types of cancer, may have beneficial effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

Hematoxylin&eosin and oil red O staining of liver sections.

We used long-term pharmacological activation of p53 by i.p. or oral administration of low-dose doxorubicin in different animal models of NAFLD (high fat diet containing 45% and 60% kcal fat) and NASH (methionine- and choline-deficient diet and choline deficiency combined with high fat diet). We also administered doxorubicin in mice lacking p53 in the liver and in two human hepatic cells lines (HepG2 and THLE2).

The attenuation of liver damage was accompanied by the stimulation of fatty acid oxidation and decrease of lipogenesis, inflammation, and ER stress. The effects of doxorubicin were abrogated in mice with liver-specific ablation of p53. Finally, the effects of doxorubicin on lipid metabolism found in animal models were also present in two human hepatic cells lines, in which the drug stimulated fatty acid oxidation and inhibited de novo lipogenesis at doses that did not cause changes in apoptosis or cell viability.

These data provide new evidence for targeting p53 as a strategy to treat liver disease


Older posts

© 2018 Sabio lab

Theme by Anders NorenUp ↑